Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy

Citations Over TimeTop 10% of 2017 papers

Abstract

Duchenne muscular dystrophy (DMD) is characterized by muscle degeneration and progressive weakness. There is considerable inter-patient variability in disease onset and progression, which can confound the results of clinical trials. Here we show that a common null polymorphism (R577X) in ACTN3 results in significantly reduced muscle strength and a longer 10 m walk test time in young, ambulant patients with DMD; both of which are primary outcome measures in clinical trials. We have developed a double knockout mouse model, which also shows reduced muscle strength, but is protected from stretch-induced eccentric damage with age. This suggests that α-actinin-3 deficiency reduces muscle performance at baseline, but ameliorates the progression of dystrophic pathology. Mechanistically, we show that α-actinin-3 deficiency triggers an increase in oxidative muscle metabolism through activation of calcineurin, which likely confers the protective effect. Our studies suggest that ACTN3 R577X genotype is a modifier of clinical phenotype in DMD patients.

Related Papers

• → miR‐31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy(2011)153 cited
• → The Frequency of Revertants in mdx Mouse Genetic Models for Duchenne Muscular Dystrophy(1992)140 cited
• → Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin(2014)35 cited
• → Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy(2018)12 cited